MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Pharma

'No weakness' in Madrigal's Rezdiffra MASH launch, says CEO

With sales of $103M in Q4 and $180M in its first nine months on the market, Madrigal's MASH treatment Rezdiffra has all the earmarks of a blockbuster.

Kevin Dunleavy Feb 27, 2025 11:19am

NeuroBo Pharmaceuticals rebrands to become MetaVia

Nov 19, 2024 9:51am

Amid a new MASH market, ‘tremendous change’ is on the horizon

Nov 5, 2024 10:02am

Novo Nordisk's semaglutide delivers in phase 3 MASH study

Nov 1, 2024 10:38am

Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3

Oct 31, 2024 3:24pm

Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia

Oct 18, 2024 8:20am